Navigation Links
QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
Date:5/4/2010

ith MoxDuo IR," added Holaday.  "Our Dual-Opioid™ formulation provides improved pain relief and greater tolerability as each drug component acts on different receptors.  This means we can enhance analgesia without significantly increasing side effects."

Among all groups, the most common moderate to severe adverse events were CNS (i.e. dizziness, somnolence, etc.) with an incidence range of 10% to 15%; gastrointestinal (i.e. nausea, emesis, etc.) with an incidence range of 15% to 30%; and dermatological (i.e. itchiness, skin rash, etc.) with an incidence range of 2% to 6%.  The percentage of patients in the MoxDuo IR group who reported moderate to severe vomiting was less than seen in previous studies and this was the only side effect that occurred more frequently with MoxDuo IR than its half-dose components.

"Having satisfied the combination rule requirement, we now turn our attention to the second and final MoxDuo IR registration trial, a study to evaluate the effectiveness of MoxDuo IR in patients following total knee replacement surgery, which was initiated in February 2010 and projected to complete dosing in Q3 2010," said Holaday.

Forward Looking Statements

This release contains forward-looking statements.  Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations.  Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement.  These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma.  Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any o
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
2. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
3. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
4. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
5. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
6. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
7. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
8. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
9. BetterInvesting Magazine Releases Julys Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
10. QRS Diagnostic Releases 64-bit and Windows(R) 7 Compatible Software
11. BioVigil Releases Second-Generation Hand Hygiene Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... be hosting its sixth Medical Affairs ... 12:30PM (EDT) via a virtual roundtable to discuss ... Research." Best Practices, Medical Affairs Consortium ... sharing insights about the key challenges they face. ...
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ... termination of its participation in the co-development ... STO:AZN and NYSE: AZN ).  Brodalumab, ... for patients with moderate-to-severe plaque psoriasis, psoriatic ... based on events of suicidal ideation and ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... MISSISSAUGA, Ontario, March 29, 2011 GlaxoSmithKline (GSK) and ... (TSX: VRX) announced today that the European Commission has ... (add-on) treatment of partial onset seizures (a form of ... in one side of the brain), with or without ...
... Metabolic Solutions Development Company (MSDC), a drug discovery ... treat metabolic diseases, announced today that it has ... company,s second drug candidate for the treatment of ... and placebo-controlled clinical trial will involve approximately 125 ...
Cached Medicine Technology:GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 2GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 3GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 4GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 5Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2
(Date:5/25/2015)... NY (PRWEB) May 26, 2015 ... Anne King as a 2015-2016 inductee into ... is recognized with this prestigious distinction for leadership in ... exclusively for professional women, boasting more than 700,000 members ... pleased to welcome Anne into this exceptional group of ...
(Date:5/25/2015)... City, NY (PRWEB) May 26, 2015 ... honors Laquanis Hooker as a 2015-2016 inductee into its ... recognized with this prestigious distinction for leadership in dentistry. ... professional women, boasting more than 700,000 members and over ... welcome Laquanis into this exceptional group of professional women,” ...
(Date:5/25/2015)... (PRWEB) May 26, 2015 ... honors Dr. Heather Stanley-Christian as a ... Year Circle. She is recognized with this prestigious ... nation's leading networking organization exclusively for professional women, ... operating local chapters. , "I'm pleased to welcome ...
(Date:5/25/2015)... The National Association of Professional ... as a 2015-2016 inductee into its VIP Woman of ... distinction for leadership in biomedical engineering. NAPW is the ... more than 700,000 members and over 200 operating Local ... exceptional group of professional women," said NAPW President Star ...
(Date:5/25/2015)... 25, 2015 World Patent Marketing, a ... The Preventer, a home patent that aims to protect ... , "House fires cost the United States a total ... and Creative Director of World Patent Marketing . ... homes that have no alarmed protection. With the use ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Anne King, Operating Principal at Keller Williams, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Dr. Heather Stanley-Christian, Systems Chair/Maternal Fetal Medicine at Stroger Hospital, into Its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 3
... Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of Pain ... King Extends Tender Offer Through December 19, 2008 ... N.J., Nov. 24 King Pharmaceuticals, Inc. (NYSE: KG ... that the two companies have signed a definitive merger agreement under ...
... Nov. 24 Transdel,Pharmaceuticals, Inc. (OTC Bulletin Board: ... and commercialization of non-invasive,topically targeted medications, today announced ... Company,s Board of Directors. , ... Swann, Inc., a consulting firm specializing in,marketing and ...
... resorts,are opening for the season, the Kelly Brush Foundation kicked ... the announcement of,over $20,000 in grants to ski racing clubs ... campaign to promote and improve ski racing safety. , ... of the most prestigious racing programs in,the nation including the ...
... DaVita Inc., a,leading provider of kidney care services ... kidney failure, continues to enhance DaVita.com to,make it ... well as a valuable,resource for patient education. DaVita.com/physicians ... people with chronic kidney disease and can,be found ...
... 24 ATS Medical, Inc.,(Nasdaq: ATSI ... and services, today announced that the first three ... completed by Dr. Allan,Stewart, Director, Aortic Surgery Program ... York ( http://www.ctsnet.org/home/allanstewart ) on November 17,and 18, ...
... ,Tis may be the season to be jolly but,tis ... lines that,barely move and public places stuffed with wheezing, sneezing ... makes keeping fit and healthy a bit of a challenge. ... find,Life123.com a comforting, mouse-click away. If you feel a ...
Cached Medicine News:Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 2Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 3Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 4Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 5Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 6Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 7Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 8Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 9Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 2Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 3Health News:Kelly Brush Foundation Awards Ski Racing Safety Grants 2Health News:DaVita.com Launches Physician Website 2Health News:DaVita.com Launches Physician Website 3Health News:ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States 2Health News:ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States 3Health News:Staying Healthy This Holiday Season Can be as Easy as Life123 2
Designed to determine the precise length of limbal incisions and proper alignment of closing sutures. Curved marking blade with 2 mm lines spaced 1 mm apart-measures up to 10 mm. Round knurled handle...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: